Insight into the Medicinal Chemistry of EGFR and HER-2 Inhibitors

Author(s): C. Wang, H. Gao, J. Dong, F. Wang, P. Li, J. Zhang

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 11 , 2014

Become EABM
Become Reviewer
Call for Editor


Dysregulation of receptor tyrosine kinases (RTKs) in cancer cells is extremely common. Overexpression of human epidermal growth factor receptor (EGFR/HER) tyrosine kinase is correlated with tumor aetiology, progression and poor prognosis. Their activation is also observed frequently in human cancers. Therefore, RTKs have been identified as important therapeutic targets in oncology. Many therapeutic methods have been developed based on inhibition of EGFR and HER-2. Herein, we will discuss recent progress in the development of EGFR/HER-2 tyrosine kinase inhibitors. We will focus on the design strategies, pharmacological profiles and structure-activity relationships (SARs) of EGFR and HER-2 inhibitors.

Keywords: EGFR, ERBB, HER-2, structure-activity relationship, tyrosine kinase.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [1336 - 1350]
Pages: 15
DOI: 10.2174/0929867320666131119124646
Price: $65

Article Metrics

PDF: 55